argenx SE (ARGX)
| Market Cap | 54.05B +33.8% |
| Revenue (ttm) | 5.32B +70.3% |
| Net Income | 1.72B +33.9% |
| EPS | 26.21 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 31.52 |
| Forward PE | 24.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 476,347 |
| Open | 873.91 |
| Previous Close | 866.11 |
| Day's Range | 855.79 - 876.38 |
| 52-Week Range | 631.47 - 953.58 |
| Beta | -0.04 |
| Analysts | Buy |
| Price Target | 1,085.78 (+25.56%) |
| Earnings Date | Jul 23, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,085.78, which is an increase of 25.56% from the latest price.
News
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte...
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. (“Purchaser”), a wholly-own...
ARGX Reinstated by Guggenheim -- Maintains Price Target at $1185
ARGX Reinstated by Guggenheim -- Maintains Price Target at $1185
ARGX Looks 41.4% Undervalued on GF Valueâ¢
ARGX Looks 41.4% Undervalued on GF Valueâ¢
Argenx resumed with a Buy at Guggenheim
Guggenheim resumed coverage of Argenx (ARGX) with a Buy rating and $1,185 price target
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe...
A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors
Investors are becoming more open to international equities after years of U.S.-heavy portfolios, Janus Henderson Investors' Julian McManus told CNBC. McManus said "Magnificent Seven" concentration has...
IBB, REGN, ARGX, ALNY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an appr...
Corning removed from ‘US 1 List’ at BofA
BofA is renewing Argenx (ARGX) for a new term following 52 weeks on the firm’s “US 1 List” while removing Corning (GLW). The US 1 List is a collection of…
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte...
ARGX Maintained by Wedbush -- Price Target Raised to $1050
ARGX Maintained by Wedbush -- Price Target Raised to $1050
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform rating on the shares. Relevant for First Tracks Biotherapeutics (TRAX), Argenx (ARGX)…
Argenx price target raised to $1,050 from $1,000 at Wedbush
Wedbush raised the firm’s price target on Argenx (ARGX) to $1,050 from $1,000 and keeps an Outperform rating on the shares. The firm notes the company will acquire Forte Biosciences…
argenx SE To Acquire Forte Biosciences Transcript
argenx SE To Acquire Forte Biosciences Transcript
argenx Expands Immunology Pipeline with Forte Biosciences Acquisition
argenx Expands Immunology Pipeline with Forte Biosciences Acquisition
After Forte acquisition, H.C. Wainwright says First Tracks could be target
After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday’s share price and a total equity value of…
Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Forte Biosciences (FBRX) to In Line from Outperform with a price target of $77, up from $69, after Argenx (ARGX) agreed to acquire Forte for $77 per…
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for aut...
ARGX Maintained by Baird -- Price Target Raised to $932
ARGX Maintained by Baird -- Price Target Raised to $932
M&A News: Forte Biosciences Shares Leap 40% After Argenx Seals $2.2B Immunology Deal
Shares in Forte Biosciences ($FBRX) were 40% healthier in pre-market trading today after it was bought by peer Argenx ($ARGX) for $2.2 billion. Multiple Autoimmune Conditions Dutch immunology innovati...
argenx SE Transcript: M&A announcement
The acquisition brings a first-in-class anti-CD122 antibody, FB102, into the immunology pipeline, targeting large unmet needs in vitiligo and celiac disease, with potential for broader autoimmune indications. The $2.2B cash deal leverages proven development and commercialization strategies to maximize impact and supports long-term growth ambitions.
argenx SE Press release: M&A announcement
argenx SE issued a press release on July 27, 2026, disclosing material business information to investors.
argenx SE Slides: M&A announcement
argenx SE has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Argenx price target raised to $932 from $867 at Baird
Baird raised the firm’s price target on Argenx (ARGX) to $932 from $867 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which…
Forte Biosciences (FBRX) Soars 39% on Acquisition by Argenx
Forte Biosciences (FBRX) Soars 39% on Acquisition by Argenx